Working… Menu

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01187303
Recruitment Status : Completed
First Posted : August 24, 2010
Last Update Posted : November 1, 2015
Information provided by (Responsible Party):
Prof. Dr. Andreas Engert, University of Cologne

Brief Summary:
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Condition or disease Intervention/treatment Phase
Relapsed NLPHL Drug: Ofatumumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Study Start Date : May 2011
Actual Primary Completion Date : November 2013
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Ofatumumab

Intervention Details:
  • Drug: Ofatumumab
    300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: 12 months after end of treatment ]

Secondary Outcome Measures :
  1. duration of response [ Time Frame: 12 months after end of treatment ]
  2. Progression free survival [ Time Frame: 12 months after end of treatment ]
  3. adverse events [ Time Frame: 12 months after end of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • relapsed nodular lymphocyte predominant hodgkin lymphoma
  • age 18 - 75
  • review of diagnosis by experienced pathologist
  • no major organ dysfunction

Exclusion Criteria:

  • classical hodgkin lymphoma
  • CD20 antibody treatment within the last 6 months prior enrollment
  • chronic or current infectious disease requirering systemic antibiotics
  • other past or current malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01187303

Layout table for location information
1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Sponsors and Collaborators
University of Cologne
Layout table for investigator information
Principal Investigator: Andreas Engert, MD University of Cologne
Additional Information:
Layout table for additonal information
Responsible Party: Prof. Dr. Andreas Engert, Prof., University of Cologne Identifier: NCT01187303    
Other Study ID Numbers: Uni-Koeln-1432
First Posted: August 24, 2010    Key Record Dates
Last Update Posted: November 1, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents